- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00549328
Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer
November 6, 2014 updated by: GlaxoSmithKline
A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer
This study is designed to evaluate the efficacy and safety of monotherapy pazopanib (a small molecule tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGF, and c-kit) in subjects with advanced (Stage IIIB or IV) non-small cell lung cancer.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Study 109609 is a single-arm, non-randomized, single-stage Phase II study of pazopanib in subjects with Stage IIIB or IV non-small cell lung cancer who have progressed after one or two prior regimens of systemic therapy.
The study will be conducted at a limited number of institutions in the US.
A total of 40 evaluable subjects will be enrolled and treated.
Pazopanib will be given at a dose of 800mg (as determined by previous Phase I studies) orally once per day.
Subjects may continue to receive study drug for up to two years unless they experience disease progression or withdraw from treatment for other reasons, or unless the Sponsor terminates the study.
A rollover study may be available to those subjects who are exhibiting clinical benefit (stable disease or better).
Evaluable subjects will be assessed for response as the primary endpoint.
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- GSK Investigational Site
-
-
Florida
-
Fort Myers, Florida, United States, 33916
- GSK Investigational Site
-
Orlando, Florida, United States, 32806
- GSK Investigational Site
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- GSK Investigational Site
-
-
Minnesota
-
Duluth, Minnesota, United States, 55805
- GSK Investigational Site
-
-
New York
-
Buffalo, New York, United States, 14263
- GSK Investigational Site
-
-
Ohio
-
Columbus, Ohio, United States, 43219
- GSK Investigational Site
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74136
- GSK Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19106
- GSK Investigational Site
-
Sayre, Pennsylvania, United States, 18840
- GSK Investigational Site
-
-
Texas
-
Corpus Christi, Texas, United States, 78463-3069
- GSK Investigational Site
-
-
Virginia
-
Newport News, Virginia, United States, 23601
- GSK Investigational Site
-
-
Washington
-
Seattle, Washington, United States, 98109
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed consent
- Histologically- or cytologically confirmed diagnosis of Stage IIIB or IV non-small cell lung cancer.
- Failed no more than two prior chemotherapy regimens for Stage IIIB or IV non-small cell lung cancer, including a platinum-containing regimen.
- Brain metastases permitted if subject has been treated with surgery and/or radiation therapy more than 4 weeks prior to date of first dose and is stable for at least one week off steroids.
- 18 years of age or older.
- Eastern Cooperative Oncology Group performance status of at least 2.
- Measurable disease according to RECIST.
- Adequate organ system function.
- Females may be eligible to enroll if they are of non-childbearing potential (surgically sterile or post-menopausal)or are using appropriate contraception methods.
Exclusion Criteria:
- Prior malignancy - unless disease-free for at least 3 years, or have had completely resected non-melanomatous skin cancer or successfully treated in situ carcinoma.
- History or clinical evidence of central nervous system metastases or leptomeningeal carcinomatosis, except for subjects with previously-treated CNS metastases, who are asymptomatic, and have had no requirement for steroids or anti-seizure medication for one week prior to first dose of study drug.
- Clinically significant gastrointestinal abnormalities.
- Presence of uncontrolled infection.
- Corrected QT interval greater than 480 msec.
- History of significant cardiovascular condition(s).
- Poorly controlled hypertension (systolic blood pressure of 140mmHG or greater or diastolic blood pressure of 90mmHg or greater).
- History of cerebrovascular accident, pulmonary embolism, or insufficiently treated deep venous thrombosis within the past 6 months prior to first dose of study drug.
- Major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer.
- Active bleeding or diathesis.
- Hemoptysis in excess of 2.5mL within 8 weeks of first dose of study drug.
- Serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance with study procedures.
- Use of prohibited medications as defined in protocol.
- Use of an investigational agent, including an investigational anti-cancer agent within 28 days, or 5 half-lives, whichever is longer, prior to first dose of study drug.
- Prior use of any investigational or licensed anti-angiogenic agent, including thalidomide and agents that target platelet-derived growth factor. Prior treatment with bevacizumab or epidermal growth factor receptor tyrosine kinase inhibitors
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pazopanib Open-label
Single-arm, non-randomised, single-stage pazopanib monotherapy.
|
Pazopanib monotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Who Achieved Either a Confirmed Complete Response or Partial Response Per RECIST Criteria
Time Frame: Baseline through End of Study (up to 2 years)
|
The best overall response using Response Evaluation Criteria In Solid Tumors (RESIST) was measured.
Complete response is defined as the disappearance of all known lesion(s), confirmed at 4 weeks, and partial response is defined as at least a 30% decrease in the sum of the longest diameters of target lesions taken as a reference to baseline sum of the longest diameters, confirmed at 4 weeks.
No formal efficacy analyses were performed due to early termination of the study.
|
Baseline through End of Study (up to 2 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Had a Complete or Partial Response, or Stable Disease
Time Frame: Baseline through End of Study (up to 2 years)
|
Disease control was measured.
Stable disease (SD) is defined as neither partial response (at least a 30% decrease in the sum of the longest diameters of target lesions taken as a reference to baseline sum of the longest diameters, confirmed at 4 weeks) nor progressive disease (PD; a 20% increase in the sum of the longest diameters of target lesions, taken as a reference the smallest sum of the longest diameter recorded since the treatment started or the appearance of one or more new lesions.
No formal efficacy analyses were performed due to early termination of the study.
|
Baseline through End of Study (up to 2 years)
|
Progression-Free Survival
Time Frame: Baseline through End of Study (up to 2 years)
|
Progression-free survival is defined as the interval between the start of treatment and the earliest date of disease progression or death due to any cause, whichever occurs first.
No formal efficacy analyses were performed due to early termination of the study.
|
Baseline through End of Study (up to 2 years)
|
Overall Survival
Time Frame: Baseline through End of Study (up to 2 years)
|
Overall survival is defined as the time from the start of treatment until death due to any cause.
No formal efficacy analyses were performed due to early termination of the study.
|
Baseline through End of Study (up to 2 years)
|
Levels of Circulating Biomarkers in Plasma
Time Frame: Baseline through End of Study (up to 2 years)
|
Biomarkers are proteins that respond in a unique way to treatment with the study drug; however, levels of proteins were not collected for this measurement.
No formal efficacy analyses were performed due to early termination of the study.
|
Baseline through End of Study (up to 2 years)
|
Characterization of Participant Populations by Identification of Intra-tumoral Biomarkers
Time Frame: Baseline through End of Study (up to 2 years)
|
Biomarkers are proteins that respond in a unique way to treatment with the study drug; however, levels of proteins were not collected for this measurement.
No formal efficacy analyses were performed due to early termination of the study.
|
Baseline through End of Study (up to 2 years)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2008
Primary Completion (Actual)
April 1, 2009
Study Completion (Actual)
April 1, 2009
Study Registration Dates
First Submitted
October 23, 2007
First Submitted That Met QC Criteria
October 23, 2007
First Posted (Estimate)
October 25, 2007
Study Record Updates
Last Update Posted (Estimate)
November 19, 2014
Last Update Submitted That Met QC Criteria
November 6, 2014
Last Verified
November 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 109609
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer, Non-Small Cell
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on Pazopanib (GW786034)
-
Illinois CancerCare, P.C.TerminatedNon Small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)WithdrawnSarcoma | Osteosarcoma | Brain Tumor | Neuroblastoma | Wilms TumorUnited States
-
GlaxoSmithKlineCompletedCarcinoma, Renal CellUnited States
-
Illinois CancerCare, P.C.TerminatedProstate CancerUnited States
-
GlaxoSmithKlineCompletedCarcinoma, Renal CellUnited States
-
Novartis PharmaceuticalsChildren's Oncology GroupCompletedSolid TumoursUnited States, Canada, Hungary, Spain, France, Slovakia, Czechia
-
GlaxoSmithKlineCompletedSarcoma, Soft TissueBelgium, Netherlands, United Kingdom, France, Hungary
-
Washington University School of MedicineNovartisTerminatedNon-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small Cell LungUnited States
-
The Netherlands Cancer InstituteGlaxoSmithKlineCompletedSarcoma,Soft TissueNetherlands
-
National Cancer Institute (NCI)CompletedNeoplasms | LymphomaUnited States